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Randomised trials provide a way of determining the effects of
health interventions. In the simplest randomised trials, some
subjects receive an intervention and others do not. The
difference in outcomes of treated and untreated (control)
subjects provides an estimate of the effects of the
intervention.
A defining characteristic of randomised trials is that the
decision about who receives the intervention is made
randomly. That is, a random process is used to allocate
subjects to treatment and control groups.
Random allocation implies that it is not possible to predict
which group an individual subject will be allocated to. But
chance is full of surprises. Paradoxically, in the long run,
chance behaves predictably: the process of randomly
allocating a large series of subjects generates comparable
groups. Groups formed by random allocation tend to be
similar with regard to the severity and chronicity of the
subjects’ disease, and subjects’ attitudes and experiences and
social backgrounds. In fact the groups tend to be similar in all
(known and unknown) factors that are likely to influence
outcomes. Randomisation is the only mechanism that can be
relied upon to produce groups that are similar in all respects.
This similarity is important. It enables us to make inferences
about the effects of intervention, uncontaminated by other
factors. When treated and control groups consist of similar
sorts of subjects, it is fair to compare the outcomes of the two
groups. If one group is treated and another group is not, and
this is the only difference between the two groups, then
differences in their outcomes must be due to treatment.
Randomisation generates groups that are similar, but not
identical. The degree of similarity depends on the number of
subjects that are randomised. When small numbers of
subjects are randomised, there is a greater probability that
there will be important differences between groups. (Then we
say there is an ‘imbalance at baseline’.) But when large
numbers of subjects are randomised to groups the differences
between groups at baseline tend to be small. And, large or
small, differences at baseline in randomised trials are due
only to chance, which means that statistical methods can be
used to deal with them.
Statistical models can be used to estimate the probability with
which certain differences between groups will occur. This is
exploited in the analysis of trial outcomes. The standard
approach to analysis assumes that there can be only two
explanations for differences in the groups’ outcomes: either
the difference is due solely to an imbalance of randomisation,
or there is some effect of the intervention. The logic of
hypothesis testing is that if the differences between groups are
large enough that imbalances of that magnitude are unlikely
to occur then the effect must be due to the intervention.
Methods of randomisation
Simple randomisation  Randomisation can be achieved by
simple processes such as coin-tossing (‘heads = control, tails
= treatment’) or drawing lots. These methods can generate
allocation schedules that are essentially random. However
they are open to abuse (a researcher might decide he or she
doesn’t like the toss and toss the coin again), and they are
difficult to audit, so they are not the best way of randomising
subjects.
A better way to randomise involves using a computer to
generate a random number for each subject in the trial. Then
a simple rule is used to assign the subject to a group on the
basis of the random number. (For example, it might be that all
subjects assigned random numbers in the lower half of the
random number distribution are allocated to the control group
and all subjects assigned random numbers in the upper half of
the random number distribution are allocated to the treatment
group.)
Simple randomisation is perfectly adequate for almost all
trials. However many researchers use more sophisticated
methods of randomisation, some of which are described in the
remainder of this Research Note.
Imbalance in sample size and blocking  Simple randomisation
does not ensure that the groups will be the same size. For
example, in a trial of 100 subjects there is only about an 8%
chance that simple randomisation will allocate exactly 50
subjects to each group, and there is about a 5% chance that
the imbalance in subject numbers will be greater than 60:40
(Piantadosi 1997).
Large imbalances in sample size may appear a bit alarming,
but they are of little consequence. The only real cost of an
imbalance in sample size is that it produces a small reduction
in statistical power. When the sample size is unbalanced, each
subject effectively provides slightly less information than
when the sample size is perfectly balanced. A trial with a
60:40 imbalance in sample size will have the same power as
a balanced trial with 13% more subjects.
Some researchers would prefer to randomise in a way that
ensures balanced sample sizes. This is called ‘blocked’
allocation. Blocked random allocation involves first setting
up a ‘block’ containing equal numbers of treatment and
control group allocations and then assigning each subject an
allocation (treatment or control) that is randomly selected
from the block. For example, in a trial of 100 subjects the
researcher might divide the block of 100 allocations into 50
treatment group allocations and 50 control group allocations.
Subjects would then be assigned a randomly selected
allocation. This procedure will generate balanced sample
sizes provided the trial terminates as planned at 100 subjects.
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Blocking is analogous to drawing allocations out of a hat
containing equal numbers of treatment and control group
allocations without returning allocations to the hat after they
are drawn. But again, generation of a blocked random
allocation schedule is best done by computer.
One limitation of this approach is that sample size will only
be balanced if the trial runs its full course. If for any reason it
is necessary to terminate the trial early the sample sizes may
be unbalanced. To protect against this contingency, some
researchers randomise multiple blocks. For example, in a trial
of 60 subjects there could be 10 consecutive blocks of 6, each
containing 3 allocations to the control group and 3 allocations
to the treatment group. If the trial is stopped early it may be
possible to stop at the end of a block, in which case the
sample sizes in the two groups will be balanced. Even if it is
not possible to stop at the end of a block, the maximum
imbalance of sample size is just half the block size.
The use of multiple blocks introduces another problem. It is
important that the person who recruits subjects into the trial is
not aware of the group to which the next subject is to be
allocated. (This is called ‘concealment’; Schulz and Grimes
2002.) But blocking introduces patterns into the allocation
schedule which might, in some circumstances, allow the
recruiter to predict some allocations. To avoid this problem,
some researchers vary the block sizes. Varying block sizes at
random (‘randomly permuted blocks’) reduces the
predictability of the allocation schedule.
Imbalance in prognostic factors and stratification  Blocking
ensures balance in sample size, but it does not ensure balance
in prognostic characteristics. With simple random allocation
or blocked random allocation it is possible that there will be
moderate differences, and occasionally even large
differences, in prognostic factors between groups. Some
researchers use statistical tests to determine if there are
baseline differences between groups, and some use statistical
techniques (such as ANCOVA) to adjust for statistically
significant baseline imbalances. But it is to be expected that
there will be some statistically baseline differences between
groups at baseline. It is not logical to test for baseline
imbalances; baseline imbalances do not produce bias, and
correcting for them can introduce bias.
As Pocock et al (2002) and others have pointed out, it is
illogical to use statistical tests to detect baseline imbalances
in prognostic variables. Hypothesis tests tell us if the
differences between groups are larger than those expected to
occur by chance when we randomly allocate subjects to
groups. But we know that baseline differences between
groups in randomised trials occurred by chance, because we
know subjects were randomly allocated to groups — in
randomised trials all statistically significant differences at
baseline must be statistical errors. (In statistical parlance, they
are ‘Type I errors’.) The probability of making statistical
errors when testing for baseline imbalances will often be
high. If, for example, a researcher tests for imbalances in 10
baseline variables, the probability of finding an imbalance
can be as high as 40%.
There are good reasons to ignore baseline imbalances of
prognostic variables in randomised trials. First, large and
overt imbalances in one direction on one prognostic variable
may be balanced by small and covert imbalances in the other
direction in other variables. So apparent imbalances in
prognostic factors may be illusory. Even when apparent
imbalances are real (so that one group truly has a better
overall prognosis than another) they need not be of concern
because they are fully accounted for in the usual statistical
testing procedures. Statistical tests tell us if the apparent
effects of treatment are big enough that they probably would
not be produced by the randomisation process alone. In fact
attempts to deal with baseline imbalances, using statistical
techniques such as ANCOVA, can be counter-productive. The
process of identifying baseline imbalances and adjusting for
them can produce (not reduce) bias, and can reduce statistical
power (Schluchter and Forsythe 1985, Raab et al 2000).
The preceding paragraphs argue that, provided there was
some form of random allocation of subjects to groups, there
is little reason to be concerned about baseline imbalances in
prognostic factors. Nonetheless there are methods of
randomising that are specifically designed to minimise
baseline imbalances. The advantage of minimising baseline
imbalances (before they happen, rather than correcting for
them after they occur) is that this can increase statistical
power. The simplest way to do this is with stratification.
Stratified random allocation involves first identifying
important prognostic factors and then separately randomising
blocks containing different levels of the prognostic factor.
The prognostic factors that are most commonly stratified are
disease severity and, in multi-site, trials, the site at which the
subject is treated. For example, in the trial by Bø and
colleagues (1999) of interventions for stress urinary
incontinence, the researchers separately randomised one
block containing only subjects with mild incontinence (pad
test < 20 g) and another block containing only subjects with
more severe incontinence (pad tests > 20 g). The effect was to
ensure balance in the stratified factor at baseline. Bø and
colleagues could know that all of the experimental groups
(there were three groups in this trial) contained equal
numbers of subjects with mild incontinence, and all three
groups contained equal numbers of subjects with more severe
incontinence.
While stratified allocation potentially increases statistical
power, there are some practical disadvantages. First, it is
generally only possible to stratify by one (or perhaps in big
trials, two or three) prognostic factors, yet there may be
several important prognostic factors. It is usually not
practically possible to stratify by all important prognostic
factors. (This means that stratification, on its own, is a very
poor way of assembling comparable groups. It is the
randomisation that makes groups comparable; stratification
simply augments randomisation by ensuring balance of one
or a few key prognostic variables.) Another limitation is that
stratification must be blocked if it is to be useful (Lavori et al
1983). It is difficult to match block sizes so that each stratum
fills at approximately the same time. So there is the risk that,
as the trial nears completion, the researchers will have to
discontinue recruitment into one stratum while they wait for
another stratum to fill up. This is particularly a problem when
some strata are very small. (Small strata often occur when
stratification is by site, because some sites may expect to
recruit only small numbers of subjects.)
Adaptive allocation  Adaptive randomisation schedules adapt
as the trial proceeds. With adaptive allocation, each subject’s
allocation depends on the baseline imbalances that exist up to
that point in the conduct of the trial; the subject’s allocation is
such that it is likely to reduce any imbalances that exist. The
most widely used method of adaptive allocation is called
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‘minimisation’. The essential feature of minimisation (there
are different types of minimisation) is that each subject is
allocated to the group which minimises some measure of
overall imbalance, so it is not strictly a randomised
procedure. Minimisation produces tighter control of baseline
imbalances than simple randomisation or stratified random
allocation (Scott et al 2004), although it can still only balance
known and measurable prognostic factors. It is a little more
complex to implement than stratified random allocation, but
it does not suffer from the practical disadvantages of stratified
allocation that are described above.
Summary
Randomisation provides a logical basis for making inferences
about effects of intervention from clinical trials. Simple
randomisation procedures are sufficient for this purpose.
More complex randomisation procedures may produce small
increases in statistical power. Blocking ensures balance in
sample sizes provided the trial is terminated at the end of a
block. In addition, blocking can reduce imbalances in sample
size even when the trial does not terminate at the end of a
block. Stratification can reduce baseline imbalances in one or
a small number of key prognostic variables, but introduces
significant practical difficulties. Minimisation overcomes
those difficulties, and can provide tight control of balance of
multiple prognostic factors.
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